China Biopharmaceutical Industry Report, 2004
  • Oct/2004
  • Hard Copy
  • USD $900
  • Pages:150
  • Single User License
    (PDF Unprintable)       
  • USD $1,000
  • Code:
  • Enterprise-wide License
    (PDF Printable & Editable)       
  • USD $1,500
  • Hard Copy + Single User License
  • USD $1,100


1.Definition, classification and characteristics of the biopharmaceutical industry
1.1 Definition and classification
1.2 Index analysis of biomedicine
1.2.1 High technology
1.2.2 Large investment
1.2.3 Long periodicity
1.2.4 High risks
1.2.5 High profitability
1.2.6 Obstacles to enter
1.2.7 Growth of the industry
1.3 Related industries’ development
1.3.1 Sector of biomedical engineering 
1.3.2 Sector of biomedical materials 
1.3.3 Medical treatment packaging industry
1.3.4 Biochip industry

2.Development of the international biopharmaceutical industry
2.1 Global biopharmaceutical market scale
2.1.1 Characteristics of the overseas biopharmaceutical industry’s development
2.1.2 General scale of the global biopharmaceutical industry
2.2 Listed biotech companies in the world
2.2.1 Operation analysis
2.2.2 Major biopharmaceutical companies’ operation status in 2003.
2.3 Status of major biopharmaceutical markets in the world
2.3.1 General situation
2.3.2 Global gene engineering industry
2.3.3 Analysis and forecast of the therapeutic albumen market, 2002-2010
2.4 Trends of global biopharmaceutical industry
2.4.1 Forecasts 
2.4.2 The best-selling biomedicine products 
2.4.3 Medicines that are under development and will soon be put into production 

3.Operation status of the biopharmaceutical industry in major regions
3.1 The United States 
3.1.1 American biotechnology saw a rise in 2003
3.1.2 Biotech companies become the investment focus
3.2 Japanese biopharmaceutical industry
3.2.1 Introduction
3.2.2 Long-term scale of Japanese biotech industry
3.2.3 Achievements of Japan’s protein structure research
3.3 European biopharmaceutical industry
3.3.1 Market share of biomedicine products
3.3.2 Development characteristics of European biotech enterprises 
3.4 German biopharmaceutical industry
3.5 Denmark biopharmaceutical industry

4.Analysis of China's pharmaceutical industry in 2003
4.1 General operation status of the pharmaceutical industry
4.1.1 Definition and classification of the industry
4.1.2 Summary of the operation status of China's pharmaceutical industry in 2003
4.2 Changes in the number of pharmaceutical enterprises
4.2.1 Changes in the number of pharmaceutical enterprises and the situation of its sub-industries. 2001-2003, by State Statistical Bureau
4.2.2 Changes regarding the number of pharmaceutical enterprises from 2001 to 2003
4.2.3 Changes regarding the number of pharmaceutical subsidiary enterprises, monitored by SETC
4.3.Analysis on the output value, profits, sales revenue growth of the pharmaceutical industry
4.3.1 Analysis on the general situation of the pharmaceutical industry, 2001-2003
4.3.2 Analysis on the pharmaceutical sub-industries., 2001-2003
4.3.3 Analysis on the profits and losses of pharmaceutical industry and its sub-industries, 2001-2003

5.China's biopharmaceutical industry
5.1 Operation status of China's biopharmaceutical industry, 2003
5.1.1 Comparison analysis of China's biopharmaceutical industry, 2001-2003 
5.1.2 Operation status of China's biopharmaceutical industry, 2003
5.1.3 Operation status of China's biopharmaceutical industry, 2002
5.1.4 Operation status of China's biopharmaceutical industry, 2001
5.2 Operation status of different types of biopharmaceutical enterprises
5.2.1 Enterprises in different scales
5.2.2 Enterprises in different economic types

6.Regional Analysis on the biopharmaceutical industry
6.1 Overall comparison 
6.1.1 Regional output ranking according to current production value, 2003
6.1.2 Regional output ranking by according to current production value, 2002
6.1.3 Comparison analysis on the performances of different regions in 2003
6.2 Operation status of the biopharmaceutical industry in Hubei, 2003
6.3 Operation status of the biopharmaceutical industry in Zhejiang, 2003
6.4 Operation status of the biopharmaceutical industry in Shandong, 2003
6.5 Operation status of the biopharmaceutical industry in Shanghai, 2003
6.6 Operation status of the biopharmaceutical industry in Guangdong, 2003
6.7 Operation status of the biopharmaceutical industry in Beijing, 2003
6.8 Operation status of biopharmaceutical industry in Tianjin, 2003
6.9 Operation status of biopharmaceutical industry in Jiangsu, 2003

7.Market segmentation of China's biopharmaceutical industry
7.1 Analysis of the major products sales 
7.1.1 Sales of major biomedical drugs 
7.1.2 R&D of the gene engineering medicine
7.2 Production and sales of domestic interferon market
7.2.1 Major interferon types
7.2.2 Big market space
7.2.3 Competition is getting fiercer 
7.2.4 Time is needed for growing 
7.2.5 Current listed interferon companies
7.3 Vaccine market
7.3.1 Domestic vaccine market contains great commercial opportunities 
7.3.2 Current status of domestic vaccine manufacturers
7.3.3 Influenza vaccine market
7.3.4 Hepatitis B virus vaccine market
7.4 Other market segments
7.4.1 Human blood albumin
7.4.2 Erythropoietin
7.4.3 Interleukin
7.4.4 Colony stimulating factor
7.4.5 Human growth hormone
7.4.6 Insulin

8.Biomedicine imports and exports
8.1 Major products imported, 2003
8.2 Major products exported, 2003
8.2.1 Total exports
8.2.2 Major export destinations, export quantity and value

9.Operation status of China's leading biopharmaceutical enterprises
9.1 Ranking
9.1.1 Sales revenue and profits of the top 10 enterprises (ranking by sales revenue), 2003 
9.1.2 Top 200 biopharmaceutical enterprises (in terms of sales revenue), by State Statistical Bureau 2002
9.1.3 Top 200 biopharmaceutical enterprises (in terms of profits), by State Statistical Bureau
9.1.4 Top 100 biopharmaceutical enterprises in terms of sales revenue and profits, by SETC
9.2 Operation status of the listed biopharmaceutical companies
9.3 Case study: Beijing TIANTAN Biological Products Co,. Ltd
9.3.1 General information
9.3.2 Analysis on its operations in 2003

10.Recommendations for biopharmaceutical investment
10.1 Blank points of the biopharmaceutical investment
10.2 Biopharmaceutical investment and financing strategy
10.2.1 Investment strategy in the United States 
10.2.2 Types of biopharmaceutical investment in China
10.2.3 Venture capital investment applies in biopharmaceutical industry
10.2.4 Advance and retreat principle of biopharmaceutical investmen
General market scale of biotech industry, 1994-2003 
Increasing trends of pharmaceutical industry's profitability, by month in 2003
Enterprise number of each China's pharmaceutical sub-industry
Proportion of pharmaceutical sub-industries by production value
Sales revenue of the pharmaceutical industry and its sub-industries
Profitability of the pharmaceutical industry and its sub- industries 
Production value, sales revenue and profit growth of China's biopharmaceutical industry, 2000-2003
Increase rate of insulin market
Major biopharmaceutical products' import quantity and value 
Characteristics of the biopharmaceutical industry
Ranking of the global top 500 pharmaceutical and biotech companies
Comparison of biotech industry between 2001 and 2002
Biopharmaceutical products with higher market shares
Medicines that will be put into production in the next three years 
Basic operational status of China's pharmaceutical industry, 2003
Sales revenue and profits of the top 10 biopharmaceutical enterprises, 2003
Selected listed biopharmaceutical companies
Benefit status of major pharmaceutical sub-industries, 2003
Important agreements signed by biotech and pharmaceutical companies in 2003
Major biopharmaceutical products' export quantity and value
Major export destinations, quantity, value and average price of vaccines for human medicine
Major export destinations, quantity, value and average price of vaccines for animal medicine

China Animal Vaccine Industry Report, 2019-2025

Chinese animal vaccine industry showed a CAGR of 8% between 2013 and 2017, but it was depressed by the outbreak of African Swine Fever in 2018 with the market size edging down 2.5% on an annualized ba...

China Blood Product Industry Report, 2020-2026

With the dynamic adjustment in the catalog of medicines covered by national medical insurance system, the scope of clinical use of almost all blood products grows tremendously, so does the reimburseme...

China Vacuum Blood Collection Device Industry Report, 2019-2025

As laboratory medicine advances, favorable polices are issued and people live a better life and care more about their health, vacuum blood collection systems get increasingly used. In 2018, global vac...

China Human Vaccine Industry Report, 2019-2025

China has been the world’s biggest producer and consumer of human vaccines over four decades of planned vaccination, a program that has reduced incidence of multiple vaccine-targeted infectious diseas...

China Independent Clinical Laboratory Industry Report, 2019-2025

China's independent clinical laboratory industry is still in its infancy. In 2018, it only saw the penetration rate of about 5%, far below 40% or more in Europe, the United States and Japan. The main ...

Global and China Monoclonal Antibody Industry Report, 2019-2025

Global monoclonal antibody market can be presented as follows: 1. Monoclonal antibody drug market booms and is highly concentrated with the approvals for such drugs.Monoclonal antibody drugs have bee...

China Contract Research Organization (CRO) Industry Report, 2019-2025

The steadily growing global pharmaceutical industry where more and more new drugs have been approved, and the soaring spending on drug research and development in recent years, are a boon for global c...

China Blood Product Industry Report, 2019-2025

With the adjustment of the national medical insurance catalogue, the clinical application and reimbursement rate of almost all blood products have been greatly improved, and the market for blood produ...

China Human Vaccine Industry Report, 2018-2022

As the world’s largest producer of human vaccines, China has established a full-life-cycleregulatory system covering vaccine R&D, production, distribution, and vaccination. The lot release volum...

China Contract Research Organization(CRO) Industry Report, 2017-2021

Under the pressure from higher R&D costs, longer R&D cycle and lower R&D success rate in pharmaceutical industry worldwide, over 50 percent of pharmaceutical enterprises have had the devel...

China Vacuum Blood Collection Device Industry Report, 2017-2021

China’s vacuum blood collection device industry now flourishes after start-up and growth stages. Along with steady improvement in economic environment, rising per-capita disposable income, greater awa...

China Independent Clinical Laboratory Industry Report, 2017-2021

China's independent clinical laboratory industry started late, and is still in its infancy. In 2016, it only saw the penetration rate of about 4%, far below 40% or more in Europe, the United States an...

China Human Vaccine Industry Report, 2017-2021

The human vaccine industry presented the following main characteristics in 2016 in China: 1. Lot release volume of human vaccines declined.Affected by the illegal vaccine case in Mar 2016 in Shandong...

China Independent Clinical Laboratory Industry Report, 2016-2020

Owing to a large population base, uneven distribution of medical resources among regions, aging population, and continuous advance of health care reform, the Chinese independent clinical laboratory ma...

China Human Vaccine Industry Report, 2016-2020

Amid the unsafe domestic vaccine events, China’s human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses,touching a 5-year low. Moreover, with the improvements in...

China Animal Vaccine Industry Report, 2016-2020

Animal vaccine is a kind of biological agent that enables inoculated animals to produce active immunity for disease prevention. In recent years, European and American animal vaccine markets have seen ...

China Blood Product Industry Report, 2016-2019

Recombinant blood products have developed for many years in foreign countries, but China’s blood products are still proteins extracted from human blood. Thus, reserves and control of plasma resources ...

China Contract Research Organization (CRO) Industry Report, 2015-2018

In recent years, China's contract research organization (CRO) industry has developed rapidly, with the market size rising from RMB8.5 billion in 2007 to RMB42.6 billion in 2014, registering a CAGR of ...

2005- All Rights Reserved 京ICP备05069564号-1 京公网安备1101054484号